1986
DOI: 10.1016/0306-4522(86)90002-3
|View full text |Cite
|
Sign up to set email alerts
|

Cholinergic function and intellectual decline in Alzheimer's disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

6
177
2
1

Year Published

1990
1990
2012
2012

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 589 publications
(186 citation statements)
references
References 169 publications
6
177
2
1
Order By: Relevance
“…p< 05). 8 Visible platform loops and passes In the visible platform task the Naive PCPA+SCO group had more loops and passes than the remaining groups. which did not differ (F(6,69)=7.08, p<.000i; Naive PCPA+SCO vs. each other goup.…”
Section: 1 7 Visible Platform Search Timementioning
confidence: 95%
“…p< 05). 8 Visible platform loops and passes In the visible platform task the Naive PCPA+SCO group had more loops and passes than the remaining groups. which did not differ (F(6,69)=7.08, p<.000i; Naive PCPA+SCO vs. each other goup.…”
Section: 1 7 Visible Platform Search Timementioning
confidence: 95%
“…1) Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the depletion of high affinity nicotinic acetylcholine receptors (nAChR) and marked loss of cholinergic neurons. 2,3) Selective depletion of cholinergic neurons in the basalis of Meynert, decreased choline acetyltransferase and acetylcholinesterase activity, or down-regulation of neuronal nicotinic acetylcholine receptors suggest the roles of cholinergic deficits in Alzheimer's disease. [3][4][5][6][7][8][9][10] Donepezil, galantamine and tacrine are acetylcholinesterase inhibitors (AChEI) that have been developed for the treatment of AD under the presumption that increasing cholinergic transmission through inhibition of acetylcholinesterase will enhance cognitive function.…”
Section: Introductionmentioning
confidence: 99%
“…For example, ACh and NE levels fluctuate across the sleep-wake cycle, as hippocampal function alternates between memory encoding during wakefulness and consolidation during sleep (Hobson et al, 1975;Kafka et al, 1986;Aston-Jones et al, 1991;Hasselmo, 1999). Cholinergic and/or noradrenergic signaling can also be reduced in hippocampus during aging and neurodegenerative diseases (Carlsson et al, 1980;Tomlinson et al, 1981;Collerton, 1986;Springer et al, 1987;Bickford-Wimer et al, 1988;ChanPalay and Asan, 1989;German et al, 1992;Kasa et al, 1997). Therefore, that ACh and NE can share signaling mechanisms depending on the receptors activated raises the possibility that increased activity of one neurotransmitter may be able to compensate for loss of the other.…”
Section: Introductionmentioning
confidence: 99%